Nuvation Bio (NUVB) News
NYSE: NUVBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.80-0.01 (-0.26%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NUVB news summary
We found 4 recent headlines mentioning Nuvation Bio (NUVB): 0 in the past week and 3 in the past 30 days, most often from PR Newswire, Nasdaq. For price context, NUVB is down 0.26% at $3.80. The most recent story, "Nuvation Bio to Present at the Jefferies Global Healthcare Conference in London", was published by PR Newswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Nuvation Bio headlines
- Nuvation Bio to Present at the Jefferies Global Healthcare Conference in LondonNEW YORK, Nov. 10, 2026 /PRNewswire/ -- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that David…PR Newswire
- Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdateAchieved $45.0 million in third quarter 2026 total revenue, including $27.5 million in net product revenue for IBTROZI® (taletrectinib) IBTROZI continues to be the most prescribed ROS1 TKI and…PR Newswire
- Jazz Pharmaceuticals (JAZZ) Reports Q3 Loss, Tops Revenue EstimatesJazz (JAZZ) delivered earnings and revenue surprises of +5.13% and +2.56%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqJAZZ, NUVB
- Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026NEW YORK, Oct. 21, 2026 /PRNewswire/ -- Nuvation Bio Inc. ("Nuvation Bio") (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today…PR Newswire